Anti-diabetic doses of metformin decrease proliferation markers in tumors of patients with endometrial cancer (Q35196533)

7 August 2017

Anti-diabetic doses of metformin decrease proliferation markers in tumors of patients with endometrial cancer (English)

1 reference

7 August 2017

1 reference

Ido Laskov

1

1 reference

7 August 2017

Laura Drudi

2

1 reference

7 August 2017

Marie-Claude Beauchamp

3

1 reference

7 August 2017

Amber Yasmeen

4

1 reference

7 August 2017

Alex Ferenczy

5

1 reference

7 August 2017

Michael Pollak

6

1 reference

7 August 2017

Walter H Gotlieb

7

1 reference

7 August 2017

language of work or name

English

0 references

publication date

24 June 2014

1 reference

7 August 2017

1 reference

7 August 2017

134

1 reference

7 August 2017

607-614

1 reference

7 August 2017

3

1 reference

Epidemiology of endometrial cancer.

7 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.06.014

Endometrial cancer and obesity: epidemiology, biomarkers, prevention and survivorship

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.06.014

The impact of obesity and age on quality of life in gynecologic surgery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.06.014

Obesity, diabetes, and other factors in relation to survival after endometrial cancer diagnosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.06.014

Association between adiponectin, insulin resistance, and endometrial cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.06.014

Diabetes and risk of endometrial cancer: a population-based prospective cohort study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.06.014

Metformin and reduced risk of cancer in diabetic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.06.014

New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.06.014

Response to Bodmer et al. Metformin and the risk of cancer: time-related biases in observational studies. Diabetes care 2012;35:2665-2673.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.06.014

Metformin use and endometrial cancer survival

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.06.014

Investigating metformin for cancer prevention and treatment: the end of the beginning

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.06.014

Potential applications for biguanides in oncology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.06.014

Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.06.014

The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.06.014

Single phosphorylation sites in Acc1 and Acc2 regulate lipid homeostasis and the insulin-sensitizing effects of metformin.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.06.014

Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.06.014

Thiazolidinediones, like metformin, inhibit respiratory complex I: a common mechanism contributing to their antidiabetic actions?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.06.014

Targeting AMPK: a new therapeutic opportunity in breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.06.014

Dysregulation of the TSC-mTOR pathway in human disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.06.014

In vitro metformin anti-neoplastic activity in epithelial ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.06.014

Discordant expression of insulin-like growth factors and their receptor messenger ribonucleic acids in endometrial carcinomas relative to normal endometrium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.06.014

Metformin is a potent inhibitor of endometrial cancer cell proliferation--implications for a novel treatment strategy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.06.014

AMPK regulates NADPH homeostasis to promote tumour cell survival during energy stress

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.06.014

Evidence for biological effects of metformin in operable breast cancer: a pre-operative, window-of-opportunity, randomized trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.06.014

Dual effect of metformin on breast cancer proliferation in a randomized presurgical trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.06.014

Metformin in early breast cancer: a prospective window of opportunity neoadjuvant study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.06.014

A scoring system for immunohistochemical staining: consensus report of the task force for basic research of the EORTC-GCCG. European Organization for Research and Treatment of Cancer-Gynaecological Cancer Cooperative Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.06.014

Quantitative comparison of immunohistochemical staining measured by digital image analysis versus pathologist visual scoring

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.06.014

Review of the current state of whole slide imaging in pathology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.06.014

Accuracy of a remote quantitative image analysis in the whole slide images

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.06.014

Metformin potentiates the effects of paclitaxel in endometrial cancer cells through inhibition of cell proliferation and modulation of the mTOR pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.06.014

Metformin promotes progesterone receptor expression via inhibition of mammalian target of rapamycin (mTOR) in endometrial cancer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.06.014

Metformin downregulates the insulin/IGF-I signaling pathway and inhibits different uterine serous carcinoma (USC) cells proliferation and migration in p53-dependent or -independent manners

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.06.014

Metformin and the risk of endometrial cancer: a case-control analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.06.014

Comparison of immunohistochemistry by automated cellular imaging system (ACIS) versus fluorescence in-situ hybridization in the evaluation of HER-2/neu expression in primary breast carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.06.014

IGFBP7 binds to the IGF-1 receptor and blocks its activation by insulin-like growth factors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.06.014

Serum insulin-like, growth factor binding protein-related protein 1 (IGFBP-rP1) and endometrial cancer risk in Chinese women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.06.014

10.1016/J.YGYNO.2014.06.014

7 January 2021

Identifiers

DOI

1 reference

7 August 2017

1 reference